11.01.18
Horizon Discovery Group has developed a set of precisely defined cell line-derived reference standards to support Biocartis’ recently launched Idylla™ microsatellite instability (MSI) Assay.
The Idylla™ MSI Assay (RUO) allows for qualitative detection of a novel panel of seven monomorphic homopolymer biomarkers to identify human cancers with microsatellite instability (MSI), in a fully automated manner. The Assay uses formalin-fixed, paraffin-embedded (FFPE) tissue sections from human cancer tissue, from which nucleic acids are extracted, amplified and then analyzed. Horizon’s newly developed MSI FFPE reference standards enable validation and routine monitoring of MSI testing on the Idylla™ platform.
Dr Chris Lowe, head of Research Operations, Horizon Discovery, said, “Horizon pioneered the development of genetically defined, well-characterized cell line derived reference standards, and this collaboration with Biocartis further validates our position as the leader in the field. Our teams are continually innovating to expand this range and we are proud to offer a sustainable source of reference material to support accurate assay results when examining MSI on the Idylla™ platform.”
Erwin Sablon, vice president Alliance Management & Partnerships of Biocartis, said, “The collaboration between Biocartis and Horizon has contributed greatly to the successful market launch of the Idylla™ MSI Assay in July 2018. We continue to be impressed with the quality of Horizon’s reference standards.”
The Idylla™ MSI Assay (RUO) allows for qualitative detection of a novel panel of seven monomorphic homopolymer biomarkers to identify human cancers with microsatellite instability (MSI), in a fully automated manner. The Assay uses formalin-fixed, paraffin-embedded (FFPE) tissue sections from human cancer tissue, from which nucleic acids are extracted, amplified and then analyzed. Horizon’s newly developed MSI FFPE reference standards enable validation and routine monitoring of MSI testing on the Idylla™ platform.
Dr Chris Lowe, head of Research Operations, Horizon Discovery, said, “Horizon pioneered the development of genetically defined, well-characterized cell line derived reference standards, and this collaboration with Biocartis further validates our position as the leader in the field. Our teams are continually innovating to expand this range and we are proud to offer a sustainable source of reference material to support accurate assay results when examining MSI on the Idylla™ platform.”
Erwin Sablon, vice president Alliance Management & Partnerships of Biocartis, said, “The collaboration between Biocartis and Horizon has contributed greatly to the successful market launch of the Idylla™ MSI Assay in July 2018. We continue to be impressed with the quality of Horizon’s reference standards.”